Diabetes and weight-loss medications, known as GLP-1 or incretin drugs, have taken the world by storm — especially the United ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.

Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide, the active ingredient in Ozempic and Wegovy.

Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular ...

Food manufacturers are trying to whip themselves up a forkful of the slimming trend — but nutrition experts aren’t giving them a good review.

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Coverage is usually for four months but can be extended if you lose 5% of your body weight. The newest weight loss drug that costs $1,000 is Zepbound. But most weight loss drugs, including Ozempic and ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland could disrupt one export that is wildly popular in America: ...